Form 4: Verve Therapeutics Director Lonnel Coats Granted 42,200 Stock Options

Verve Therapeutics, Inc. director Lonnel Coats was granted 42,200 stock options at an exercise price of $5.73 per share as part of the company's director compensation program.

Summary

• Lonnel Coats, a Director of Verve Therapeutics, Inc. (VERV), acquired 42,200 stock options.
• The transaction date for the option grant was June 5, 2025.
• The exercise price for these stock options is $5.73 per share.
• The options have an expiration date of June 4, 2035.
• These options were issued under the 2021 Stock Incentive Plan of Verve Therapeutics, Inc., as part of its director compensation program.
• The options vest upon the earlier of the one-year anniversary of the grant date or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to Mr. Coats' continued service as a director.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event that aligns director interests with shareholders, which is generally viewed favorably, but it does not indicate any new operational or financial performance.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term performance and value creation.
• The transaction is part of a pre-existing, approved compensation plan (2021 Stock Incentive Plan), indicating structured corporate governance.

Future Outlook

The vesting schedule indicates that the options will become exercisable upon the earlier of the one-year anniversary of the grant date or immediately prior to the first annual meeting of stockholders occurring after the grant date, contingent on the director's continued service.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically the grant of equity compensation to a director. Such grants are a common practice across industries, particularly in biotechnology and pharmaceutical sectors, to attract and retain experienced board members and align their financial incentives with company performance.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice in publicly traded companies, especially within the biotech industry, to incentivize long-term commitment and performance.
• The vesting schedule, tied to continued service and an annual meeting, is typical for director equity awards, similar to compensation structures seen at companies like Moderna (MRNA) or CRISPR Therapeutics (CRSP) for their non-employee directors.

Corporate Governance

Related Party Transactions

• The grant of stock options to Lonnel Coats, a director, constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the financial interests of Director Lonnel Coats with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• Continued service of Lonnel Coats as a director of Verve Therapeutics, Inc. for the options to vest.
• The options will vest upon the earlier of the one-year anniversary of the grant date or immediately prior to the first annual meeting of stockholders occurring after the grant date.

Key Dates

Keywords

Verve Therapeutics, VERV, Lonnel Coats, Stock Option, Director Compensation, Insider Transaction, Form 4, Equity Compensation